The results of the administration of the nona-peptide inhibitor (SQ 20,881) of the enzymatic conversion of angiotensin I into angiotensin II in twelve severe hypertensive patients are presented. 2. Administration of the compound was associated with a fall in blood pressure in ten of twelve patients. 3. Four patients had a normal plasma renin activity (PRA) with a range of 1.6-3.7 ng h-1 ml-1 and eight patients had a high PRA with a range of 5.0-74 ng h-1 ml-1. Two of the patients with normal PRA had no fall in blood pressure despite receiving 2 mg/kg of the compound. Two patients with normal PRA, however, did respond, thus indicating that a high PRA is not necessary for a response to the inhibitor compound. 4. It was found that haemodialysis or diuresis with frusemide enhanced the blood pressure response to the compound. 5. The presence of a measured low total blood volume was found to be associated with an exaggerated fall in blood pressure to a small dose of compound (0.125 mg/kg) in one patient.
摘要
本文呈现了在12名重度高血压患者中使用血管紧张素I酶促转化为血管紧张素II的九肽抑制剂（SQ 20,881）的结果。2. 给这12名患者中的10名使用该化合物后，血压下降。3. 4名患者的血浆肾素活性（PRA）正常，范围为1.6 - 3.7 ng h-1 ml-1，8名患者的PRA较高，范围为5.0 - 74 ng h-1 ml-1。两名PRA正常的患者在接受2 mg/kg该化合物后血压未下降。然而，另外两名PRA正常的患者有反应，这表明对抑制剂化合物有反应并不一定需要高PRA。4. 发现血液透析或使用速尿利尿可增强对该化合物的血压反应。5. 发现一名患者测量的低总血容量与小剂量化合物（0.125 mg/kg）引起的血压过度下降有关。
